Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
Takeda Pharmaceutical and its plasma peers could launch clinical trials in Japan, the US, and Europe as early as July for their unbranded hyperimmune globulin therapy for the treatment of COVID-19. Julie Kim, president of Takeda’s Plasma-Derived Therapies Business Unit,…
To read the full story
Related Article
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Takeda, CSL, Other Firms Join Hands to Develop Unbranded Immunoglobulin for COVID-19
April 7, 2020
- Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
March 5, 2020
BUSINESS
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
- Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
- Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
- SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
- Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…